Developer docs
API playgroundTry for free, no card

Search company profiles

Synaxys

Full company profile

uuid002gena

Namestring
Synaxys
Legal namestring
SYNAXYS SAS
Websiteurl
synaxys.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToulouse, France
HQ citystring
Toulouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical research services, neurological drug discovery, in vitro neuronal models, contract research organization, neuro-engineering platforms
Industry1 code
PRIMARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Synaxys operates as a Contract Research Organization (CRO) providing custom-designed preclinical assays and R&D projects. They offer pilot tests, neuro-pharmacology studies, and full R&D projects with comprehensive confidential reports directly usable for decision-making. Revenue is generated through service fees for customized research studies.

synaxys.com
2R&D Partnerships
TypeProfessional Services
Description

Collaborative R&D projects with public or private institutions. Synaxys participates as partner to answer research calls or as coordinator to design and manage R&D projects. Revenue may come from government grants (e.g., ANR-PRCE) and collaborative research agreements.

synaxys.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
15D-brain
Description

The first reliable human in vitro model of the nervous system for functional preclinical studies, offering 5 dimensions (X, Y, Z, time, activity) to replace animal experimentation

synaxys.com
+1 more record
Core offering1 text field

Synaxys is a Contract Research Organization providing custom-designed preclinical research services built on its proprietary 5D-brain technology, a human in vitro 3D neuronal network model. The company delivers pilot tests, neuro-pharmacology studies, and full R&D projects to pharmaceutical and biotech clients to predict human nervous system responses and evaluate neurological disease therapeutics before clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Delivers reliable preclinical data in less than 3 weeks
+2 more records
Product overview1 text field

Synaxys offers a unified platform centered on its 5D-brain product, a proprietary 3D human in vitro neuronal network model for preclinical research. The portfolio includes complementary service tiers: Pilot Tests for dose-response characterization, Neuro-pharmacology Studies for target identification, and Full R&D Projects leveraging disease-specific models (healthy reference and epileptic). The 5D-brain serves as the core enabling technology across all services, delivering functional electrophysiological data, microscopy, genomic and proteomic analysis to predict human nervous system responses before clinical trials.

Product and service4 records
15D-brain
CategoryCore Technology Platform
Description

The first reliable human in vitro model of the nervous system for functional preclinical studies, providing five accessible dimensions (X, Y, Z, time, activity) to replace animal experimentation and enhance preclinical R&D results. It is sold as the foundational technology platform underlying Synaxys' CRO service offerings.

2Pilot Tests
CategoryCRO Preclinical Service
Description

Custom-designed CRO service for characterization of dose response for client compounds compared to reference chemicals on a healthy mature 3D human neuronal network. Targeted at pharmaceutical and biotech R&D teams needing initial preclinical characterization.

3Neuro-pharmacology Studies
CategoryCRO Preclinical Service
Description

Custom CRO service covering identification of biological targets of client compounds and determination of specific characteristics compared to known drugs with similar targets. Targeted at drug discovery teams in pharma and biotech.

4Full R&D Projects
CategoryCRO Preclinical Service
Description

End-to-end custom CRO project evaluating the therapeutic potential of compounds using 5D-brain disease models, with two models currently available: healthy reference and epileptic model. Delivered as a thorough confidential report directly usable for decision-making. Targeted at pharmaceutical and biotech R&D teams.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-01
Description

Synaxys joined Eurobiomed in September 2019, a competitiveness cluster supporting healthcare innovation in the South of France, providing industry networking and partnership opportunities.

2CNRS (Centre National de la Recherche Scientifique)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

License agreement signed in December 2018 granting Synaxys rights to technologies developed at CNRS. CNRS also provided housing at ITAV research institute starting November 2017, enabling Synaxys to launch operations.

synaxys.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

License agreement signed in December 2018 alongside CNRS for technology transfer of proprietary neuro-engineering processes.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner providing scientific expertise and laboratory resources for Synaxys' neuro-engineering research activities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner contributing expertise in data analysis and computational methods for Synaxys' big data analysis capabilities.

6UT3PS (Université Toulouse III Paul Sabatier)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research partner providing scientific collaboration and research expertise in neuroscience and related fields.

synaxys.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a research partner in Synaxys' ecosystem, nature of collaboration not detailed.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins Discovery offers large-scale preclinical and discovery services including CNS/neuroscience assays, positioning it as a broad incumbent that competes with Synaxys for outsourced preclinical research contracts.

TypeDirect peer
Description

Neuroservice is a CRO specializing in electrophysiology and CNS preclinical services, making it a direct functional competitor to Synaxys for pharma outsourced neuroscience assay work.

TypeDirect peer
Description

Axol Bioscience supplies iPSC-derived neural cell types and custom neuroscience services for drug discovery, overlapping with Synaxys on human neuronal models and preclinical assay offerings.

TypeDirect peer
Description

BrainXell specializes in iPSC-derived neuron production and neural differentiation services for neuroscience drug discovery, overlapping with Synaxys on human neuronal models and preclinical assay offerings.

TypeDirect peer
Description

Ncardia provides iPSC-derived cardiac and neural cells and assay services for drug discovery, directly competing with Synaxys in human iPSC-based neuronal models for preclinical neuroscience applications.

TypeDirect peer
Description

StemoniX develops microBrain 3D human neural platforms and screening services for CNS drug discovery, making it a direct competitor to Synaxys' 5D-brain in functional neuronal assay services.

TypeBroad incumbent
Description

Charles River is a global CRO offering preclinical neuroscience safety and efficacy assessment services, representing a broad incumbent competitor that pharma clients may choose instead of specialized platforms like Synaxys.

TypeEmerging player
Description

bit.bio programs iPSCs into mature human cell types at scale using its opti-ox technology, supplying defined neuronal populations that compete with parts of Synaxys' human neuron differentiation pipeline.

TypeEmerging player
Description

Mimetas develops organ-on-chip and 3D tissue models for drug discovery including neurological applications, intersecting with Synaxys' 3D human in vitro preclinical approach.

TypeBroad incumbent
Description

Fujifilm CDI is a major supplier of iPSC-derived cells including iCell neurons, providing off-the-shelf human neuronal cells that partially substitute for Synaxys' custom 5D-brain models in pharma screening workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synaxys

Preclinical Contract Research Servicessynaxys.com

Synaxys firmographics

Firmographics
Name
Synaxys
Legal name
SYNAXYS SAS
Website
https://synaxys.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Synaxys industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Preclinical research services
  • Neurological drug discovery
  • In vitro neuronal models
  • Contract research organization
  • Neuro-engineering platforms

Where Synaxys is headquartered

Location

Headquarters

HQ city
Toulouse
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Synaxys business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services: Synaxys operates as a Contract Research Organization (CRO) providing custom-designed preclinical assays and R&D projects. They offer pilot tests, neuro-pharmacology studies, and full R&D projects with comprehensive confidential reports directly usable for decision-making. Revenue is generated through service fees for customized research studies.
  2. R&D Partnerships: Collaborative R&D projects with public or private institutions. Synaxys participates as partner to answer research calls or as coordinator to design and manage R&D projects. Revenue may come from government grants (e.g., ANR-PRCE) and collaborative research agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Synaxys product offering

Product offering

Core offering

Synaxys is a Contract Research Organization providing custom-designed preclinical research services built on its proprietary 5D-brain technology, a human in vitro 3D neuronal network model. The company delivers pilot tests, neuro-pharmacology studies, and full R&D projects to pharmaceutical and biotech clients to predict human nervous system responses and evaluate neurological disease therapeutics before clinical trials.

Product overview

Synaxys offers a unified platform centered on its 5D-brain product, a proprietary 3D human in vitro neuronal network model for preclinical research. The portfolio includes complementary service tiers: Pilot Tests for dose-response characterization, Neuro-pharmacology Studies for target identification, and Full R&D Projects leveraging disease-specific models (healthy reference and epileptic). The 5D-brain serves as the core enabling technology across all services, delivering functional electrophysiological data, microscopy, genomic and proteomic analysis to predict human nervous system responses before clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • 5D-brain: The first reliable human in vitro model of the nervous system for functional preclinical studies, offering 5 dimensions (X, Y, Z, time, activity) to replace animal experimentation
  • 5D-BRAIN

Products and services

  • 5D-brain The first reliable human in vitro model of the nervous system for functional preclinical studies, providing five accessible dimensions (X, Y, Z, time, activity) to replace animal experimentation and enhance preclinical R&D results. It is sold as the foundational technology platform underlying Synaxys' CRO service offerings.
  • Pilot Tests Custom-designed CRO service for characterization of dose response for client compounds compared to reference chemicals on a healthy mature 3D human neuronal network. Targeted at pharmaceutical and biotech R&D teams needing initial preclinical characterization.
  • Neuro-pharmacology Studies Custom CRO service covering identification of biological targets of client compounds and determination of specific characteristics compared to known drugs with similar targets. Targeted at drug discovery teams in pharma and biotech.
  • Full R&D Projects End-to-end custom CRO project evaluating the therapeutic potential of compounds using 5D-brain disease models, with two models currently available: healthy reference and epileptic model. Delivered as a thorough confidential report directly usable for decision-making. Targeted at pharmaceutical and biotech R&D teams.

Quantifiable outcome

  • Delivers reliable preclinical data in less than 3 weeks
  • +2 more outcomes

Companies that use Synaxys

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Synaxys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Synaxys partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • EurobiomedcoreStrategic or Co-development Partner · 1 September 2019Synaxys joined Eurobiomed in September 2019, a competitiveness cluster supporting healthcare innovation in the South of France, providing industry networking and partnership opportunities.
  • CNRS (Centre National de la Recherche Scientifique)coreStrategic or Co-development Partner · 1 December 2018License agreement signed in December 2018 granting Synaxys rights to technologies developed at CNRS. CNRS also provided housing at ITAV research institute starting November 2017, enabling Synaxys to launch operations.
  • SATT-TTT (Société d'Accélération de Transfert de Technologies Toulouse Tech)coreStrategic or Co-development Partner · 1 December 2018License agreement signed in December 2018 alongside CNRS for technology transfer of proprietary neuro-engineering processes.
  • LAAS-CNRS (Laboratoire d'Analyse et d'Architecture des Systèmes)minorStrategic or Co-development PartnerResearch partner providing scientific expertise and laboratory resources for Synaxys' neuro-engineering research activities.
  • IRIT (Institut de Recherche en Informatique de Toulouse)minorStrategic or Co-development PartnerResearch partner contributing expertise in data analysis and computational methods for Synaxys' big data analysis capabilities.
  • UT3PS (Université Toulouse III Paul Sabatier)minorStrategic or Co-development PartnerAcademic research partner providing scientific collaboration and research expertise in neuroscience and related fields.
  • NUBBOminorStrategic or Co-development PartnerListed as a research partner in Synaxys' ecosystem, nature of collaboration not detailed.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Synaxys competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Discovery: Eurofins Discovery offers large-scale preclinical and discovery services including CNS/neuroscience assays, positioning it as a broad incumbent that competes with Synaxys for outsourced preclinical research contracts.
  • Charles River Laboratories: Charles River is a global CRO offering preclinical neuroscience safety and efficacy assessment services, representing a broad incumbent competitor that pharma clients may choose instead of specialized platforms like Synaxys.
  • Fujifilm Cellular Dynamics: Fujifilm CDI is a major supplier of iPSC-derived cells including iCell neurons, providing off-the-shelf human neuronal cells that partially substitute for Synaxys' custom 5D-brain models in pharma screening workflows.

Direct peers

  • Neuroservice: Neuroservice is a CRO specializing in electrophysiology and CNS preclinical services, making it a direct functional competitor to Synaxys for pharma outsourced neuroscience assay work.
  • Axol Bioscience: Axol Bioscience supplies iPSC-derived neural cell types and custom neuroscience services for drug discovery, overlapping with Synaxys on human neuronal models and preclinical assay offerings.
  • BrainXell: BrainXell specializes in iPSC-derived neuron production and neural differentiation services for neuroscience drug discovery, overlapping with Synaxys on human neuronal models and preclinical assay offerings.
  • Ncardia: Ncardia provides iPSC-derived cardiac and neural cells and assay services for drug discovery, directly competing with Synaxys in human iPSC-based neuronal models for preclinical neuroscience applications.
  • StemoniX (part of Cancer Genetics Inc./Vyant Bio): StemoniX develops microBrain 3D human neural platforms and screening services for CNS drug discovery, making it a direct competitor to Synaxys' 5D-brain in functional neuronal assay services.

Emerging players

  • bit.bio: bit.bio programs iPSCs into mature human cell types at scale using its opti-ox technology, supplying defined neuronal populations that compete with parts of Synaxys' human neuron differentiation pipeline.
  • Mimetas: Mimetas develops organ-on-chip and 3D tissue models for drug discovery including neurological applications, intersecting with Synaxys' 3D human in vitro preclinical approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Synaxys social profiles

Digital presence

Synaxys compliance and trust

Trust signal

Compliance2 records

Synaxys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synaxys leadership team

Management profile

Number of profiles

Profiles2 records

Synaxys funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synaxys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synaxys

What does Synaxys do?

Synaxys is a Contract Research Organization providing custom-designed preclinical research services built on its proprietary 5D-brain technology, a human in vitro 3D neuronal network model. The company delivers pilot tests, neuro-pharmacology studies, and full R&D projects to pharmaceutical and biotech clients to predict human nervous system responses and evaluate neurological disease therapeutics before clinical trials.

Is Synaxys a public or private company?

Synaxys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Synaxys founded?

Synaxys was founded in 2018. It employs 1 to 10 people.

Where is Synaxys based?

Synaxys is headquartered in Toulouse, France, in the Europe region.

How does Synaxys make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are R&D Partnerships.

Who are Synaxys's main competitors?

Broad incumbents on record are Eurofins Discovery, Charles River Laboratories and Fujifilm Cellular Dynamics. Direct peers are Neuroservice, Axol Bioscience, BrainXell, Ncardia and StemoniX (part of Cancer Genetics Inc./Vyant Bio). Emerging players are bit.bio and Mimetas.

Does Synaxys have an API?

No public API is recorded for Synaxys.

What industry is Synaxys in?

Synaxys's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAN, Nonclinical Study Management & Regulatory Writing (IND-enabling). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales